{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:11:27Z","timestamp":1788282687915,"version":"build-2803163510"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy of Craiova, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Abrocitinib, an oral small-molecule Janus Kinase 1 (JAK1) inhibitor, is primarily approved for treating moderate-to-severe atopic dermatitis (AD) in adults and adolescents aged 12 and older. This review examines the emerging off-label uses of Abrocitinib. We identified 37 papers reporting on the use of Abrocitinib in various conditions other than AD. The most commonly reported uses were for vitiligo, prurigo nodularis, and hand eczema, with 12 cases each. There were also 10 cases of lichen sclerosus and chronic pruritus of unknown origin and 5 cases each of pityriasis rubra pilaris alopecia areata. Additionally, erythematotelangiectatic rosacea and steroid-induced rosacea were reported in four cases each. Other conditions treated with Abrocitinib were noted, but these mostly had only one or two reported cases. Interestingly, out of the 103 patients reviewed, all studies reported favorable clinical outcomes and satisfactory results, with the exception of one isolated case where Abrocitinib was used to treat erythematotelangiectatic rosacea.<\/jats:p>","DOI":"10.3390\/life14091127","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:04:18Z","timestamp":1725851058000},"page":"1127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis"],"prefix":"10.3390","volume":"14","author":[{"given":"George G.","family":"Mitroi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Mitroi","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana Maria","family":"Ic\u0103","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Anghelina","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea Sorin","family":"Ciolofan","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela Roxana","family":"Mitroi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"ref_1","unstructured":"European Medicines Agency (2024, August 10). Committee for Medicinal Products for Human Use (CHMP) Summary of Opinion: CIBINQO (Abrocitinib), Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-opinion-cibinqo_en.pdf."},{"key":"ref_2","unstructured":"Pfizer, U.S. (2022, August 10). FDA Approves Pfizer\u2019s CIBINQO\u00ae (Abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-cibinqor-abrocitinib-adults."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino] cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1084\/jem.20082900","article-title":"Control of T helper cell differentiation through cytokine receptor inclusion in the immunological synapse","volume":"206","author":"Maldonado","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10348","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e15636","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_10","unstructured":"European Medicines Agency (2024, August 30). Cibinqo: EPAR-Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cibinqo."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Cai, Y., Shi, M., Jiang, S., Cui, S., Wu, Y., Gao, X.-H., and Chen, H.-D. (2016). The prevalence of vitiligo: A meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163806"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Qi, F., Liu, F., and Gao, L. (2021). Janus kinase inhibitors in the treatment of vitiligo: A review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.790125"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2050313X241231527","DOI":"10.1177\/2050313X241231527","article-title":"Rapid resolution of non-segmental vitiligo in a patient treated with Abrocitinib: A case report","volume":"12","author":"Satkunanathan","year":"2024","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_14","first-page":"00847-8","article-title":"A prospective observational study of oral Abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo","volume":"24","author":"Xu","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cod.14035","article-title":"Guidelines for diagnosis, prevention, and treatment of hand eczema","volume":"86","author":"Thyssen","year":"2022","journal-title":"Contact Dermat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cod.13501","article-title":"Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab","volume":"83","author":"Halling","year":"2020","journal-title":"Contact Dermat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39822","DOI":"10.2340\/actadv.v104.39822","article-title":"Real-world experience of Abrocitinib on difficult-to-treat hand eczema in Chinese patients","volume":"104","author":"Li","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"ref_18","first-page":"e414","article-title":"2020 guidelines for the diagnosis and treatment of prurigo","volume":"48","author":"Satoh","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/exd.13705","article-title":"Possible roles of basophils in chronic itch","volume":"28","author":"Hashimoto","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/derm.2022.0065","article-title":"Failure of dupilimab with severe prurigo nodularis that responded well to Abrocitinib","volume":"34","author":"Yosipovitch","year":"2023","journal-title":"Dermatitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ccr3.8606","article-title":"Successful treatment of refractory prurigo nodularis with Abrocitinib","volume":"12","author":"Sun","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","article-title":"Efficacy and safety of Abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: A nonrandomized controlled trial","volume":"160","author":"Kwatra","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1080\/09546634.2021.1880542","article-title":"Treatment of patients with chronic pruritus of unknown origin with dupilumab","volume":"33","author":"Jeon","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","first-page":"CD013128","article-title":"Interventions for chronic pruritus of unknown origin","volume":"1","author":"Andrade","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"De Luca, D.A., Papara, C., Vorobyev, A., Staiger, H., Bieber, K., Tha\u00e7i, D., and Ludwig, R.J. (2023). Lichen sclerosus: The 2023 update. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1106318"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dth.14896","article-title":"Lichen sclerosus successfully treated with baricitinib plus psoralen and ultraviolet A","volume":"34","author":"Li","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/bjd\/ljad129","article-title":"Abrocitinib as a novel treatment for lichen sclerosus","volume":"189","author":"Bao","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdcr.2024.02.010","article-title":"Treatment of plasma cell balanitis associated with male genital lichen sclerosus using Abrocitinib","volume":"46","author":"Xiong","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jdv.14761","article-title":"Pityriasis rubra pilaris: Algorithms for diagnosis and treatment","volume":"32","author":"Roenneberg","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23 Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhong, X., Huang, D., Shi, Y., and Ding, Y. (2024). Efficacy and safety of oral Abrocitinib monotherapy in pityriasis rubra pilaris. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.19992"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","first-page":"130","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jdcr.2017.12.016","article-title":"Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor","volume":"4","author":"Morris","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ajd.13836","article-title":"Successful treatment of chronic severe alopecia areata with Abrocitinib","volume":"63","author":"Bennett","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jocd.15896","article-title":"Effective treatment of refractory alopecia areata in pediatric patients with oral Abrocitinib","volume":"23","author":"Huang","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2242706","DOI":"10.1080\/09546634.2023.2242706","article-title":"Successful treatment of alopecia universalis with Abrocitinib: A case report","volume":"34","author":"Zhang","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2022.02.027","article-title":"A case of atopic dermatitis with alopecia universalis in a patient treated with Abrocitinib","volume":"22","author":"Zhao","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: Part II. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhang, T., Liu, X., Zhang, L., and Jiang, X. (2024). Treatment of rosacea with upadacitinib and Abrocitinib: Case report and review of evidence for Janus kinase inhibition in rosacea. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1416004"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.2147\/CCID.S440138","article-title":"Successful treatment of granulomatous rosacea by JAK inhibitor Abrocitinib: A case report","volume":"16","author":"Ren","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Xu, B., Xu, Z., Ye, S., Sun, H., Zhao, B., Wu, N., and Wu, J. (2023). JAK1 inhibitor Abrocitinib for the treatment of steroid-induced rosacea: Case series. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1239869"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: Ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CCID.S446369","article-title":"Abrocitinib as a novel treatment for multiple skin disorders: 3 case reports and a scoping review","volume":"17","author":"Chen","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1111\/ijd.16698","article-title":"Treatment of primary cutaneous lichenoid amyloidosis with Abrocitinib: A pilot study in two cases","volume":"62","author":"Bai","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/MJT.0000000000001671","article-title":"Effectiveness of Abrocitinib in a patient with chronic actinic dermatitis","volume":"31","author":"Jin","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1111\/jdv.19475","article-title":"Abrocitinib: A promising option for patients with refractory bullous pemphigoid","volume":"38","author":"Jiang","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ajd.14248","article-title":"Janus kinase inhibitor Abrocitinib as an off-label treatment for tattoo granuloma with uveitis (TAGU)","volume":"65","author":"Yang","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2313090","DOI":"10.1080\/09546634.2024.2313090","article-title":"Oral Abrocitinib in the treatment of granuloma annulare: A case report","volume":"35","author":"Liu","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_50","first-page":"841","article-title":"Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor Abrocitinib","volume":"22","author":"Michels","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mao, J., Du, N., Jia, Y., Mao, Q., Yang, J., Zhang, Y., Li, Y., Cao, L., and Min, W. (2024). Case report: Treatment of psoriasiform dermatitis in patients with malignancy. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1363405"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.36849\/JDD.7271","article-title":"Post-hyaluronic acid filler reaction treated with Abrocitinib: A case report","volume":"23","author":"Lopez","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ced\/llad023","article-title":"Improvement of Hailey-Hailey disease with Abrocitinib","volume":"48","author":"Li","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamadermatol.2023.0561","article-title":"Treatment of Netherton syndrome with Abrocitinib","volume":"159","author":"Zheng","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, Y., Lv, C., Zou, Q., and Zhou, K. (2024). Successful treatment of porokeratosis ptychotropica with Abrocitinib. Int. J. Dermatol.","DOI":"10.1111\/ijd.17202"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cai, L., Yan, Y., Li, Y., Lin, J., She, X., and Wang, X. (2024). Two cases of eosinophilic pustular folliculitis successfully treated with Abrocitinib. J. Dermatol.","DOI":"10.1111\/1346-8138.17284"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jin, S., Yue, C., Wang, S., and Wang, P. (2024). Oral Abrocitinib in the treatment of refractory dissecting cellulitis of the scalp: A case report. J. Dermatol.","DOI":"10.1111\/1346-8138.17232"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/PPA.S451007","article-title":"Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report","volume":"18","author":"Teng","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.2147\/CCID.S424310","article-title":"A Report of Eruptive Pruritic Papular Porokeratosis Treated with Abrocitinib","volume":"16","author":"Xia","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.2147\/CCID.S433561","article-title":"A case of perioral dermatitis successfully treated with Abrocitinib","volume":"16","author":"Teng","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/CCID.S455060","article-title":"A case of persistent pityriasis rosea successfully treated by a short course of therapy with Abrocitinib","volume":"17","author":"Wu","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1111\/jdv.19189","article-title":"Effect of Abrocitinib in a patient with extensive necrobiosis lipoidica","volume":"37","author":"Arnet","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"pe996","DOI":"10.1111\/jdv.19069","article-title":"The Janus kinase 1 inhibitor Abrocitinib for the treatment of oral lichen planus","volume":"37","author":"Solimani","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cod.14204","article-title":"Occupational airborne allergic contact dermatitis to invasive Compositae species treated with Abrocitinib: A case report","volume":"87","author":"Baltazar","year":"2022","journal-title":"Contact Dermat."},{"key":"ref_65","first-page":"806","article-title":"Understanding the potential role of abrocitinib in the time of SARS-CoV-2","volume":"20","author":"Uppal","year":"2021","journal-title":"J. Drugs Dermatol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/9\/1127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:50:04Z","timestamp":1760111404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/9\/1127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["life14091127"],"URL":"https:\/\/doi.org\/10.3390\/life14091127","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}